Yaron Daniely

Yaron Daniely

Israel
8K‏ עוקבים מעל 500 קשרים

הצטרפ/י כדי להציג פרופיל

מאמרים מאת Yaron

  • The Triumph of Innovation
    22 באפר׳ 2023

    The Triumph of Innovation

    Exactly 20 years ago I finished my postdoctoral fellowship at the Weizmann Institute of Science and took on my first…

    ‏12‏ ‏תגובות‏
  • 3D PRINTING CONFERENCE
    1 באוק׳ 2017

    3D PRINTING CONFERENCE

    Here's an event any innovative, curious, technology fan and industry expert should not miss (I certainly don't plan…

    ‏2‏ ‏תגובות‏
  • BIO-MBA מעגל שיחה לרופאים
    14 ביוני 2015

    BIO-MBA מעגל שיחה לרופאים

    מעגל שיחה לרופאים לרגל פתיחת מסלול ייחודי וקרן מלגות יעודית למועמדים שהינם רופאים חברי ההסתדרות הרפואית בישראל - יום ו'…

    ‏2‏ ‏תגובות‏
ראה את כל המאמרים

פעילות

הצטרפו עכשיו כדי לראות את כל פעילות

ניסיון

  • Lyfegen גרפי

    Lyfegen

    Basel, Switzerland

  • -

    Israel

  • -

    Israel

  • -

    Israel

  • -

    Israel

  • -

    Raanana, Israel

  • -

    Colorado, United States

  • -

  • -

    Jerusalem Area, Israel

  • -

    Rishon Le-Tziyon, Israel

  • -

    Tel Aviv Area, Israel

  • -

    Tel Aviv, Israel and Plymouth Meeting, PA (USA)

  • -

    Tel Aviv, Israel

  • -

  • -

  • -

חינוך

פרסומים

  • Characterizing the Placebo Response in Adults With ADHD.

    Journal of Attention Disorders

    ראו פרסום

  • Attention benefits after a single dose of metadoxine extended release in adults with predominantly inattentive ADHD.

    Postgraduate Medicine

    ראו פרסום

  • A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy, Safety, and Tolerability of Extended-Release Metadoxine in Adults With Attention-Deficit/Hyperactivity Disorder

    J Clin Psychiatry. 2012 Dec;73(12):1517-23. doi: 10.4088/JCP.12m07767.

    OBJECTIVE:

    To evaluate the efficacy, safety, and tolerability of an oral extended-release (ER) formulation of the nonstimulant metadoxine in the treatment of adult attention-deficit/hyperactivity disorder (ADHD).

    METHOD:

    This was a 1:1 randomized, double-blind, placebo-controlled, parallel-design, phase 2 study of metadoxine ER 1,400 mg/d treatment for 6 weeks, following a 2-week baseline/screening period, involving 120 adults with DSM-IV-defined ADHD. A follow-up…

    OBJECTIVE:

    To evaluate the efficacy, safety, and tolerability of an oral extended-release (ER) formulation of the nonstimulant metadoxine in the treatment of adult attention-deficit/hyperactivity disorder (ADHD).

    METHOD:

    This was a 1:1 randomized, double-blind, placebo-controlled, parallel-design, phase 2 study of metadoxine ER 1,400 mg/d treatment for 6 weeks, following a 2-week baseline/screening period, involving 120 adults with DSM-IV-defined ADHD. A follow-up assessment occurred 2 weeks after the trial was completed. Efficacy measures included changes in Conners' Adult ADHD Rating Scale-Investigator Rated (CAARS-INV) total ADHD symptoms score with adult ADHD prompts (primary measure), response rates (≥ 25% or 40% improvement in CAARS-INV total ADHD symptom score), Test of Variables of Attention (TOVA) performance, and Adult ADHD Quality of Life (AAQoL) total score. The study was conducted from March 15, 2011, to August 21, 2011.

    RESULTS:

    Intent-to-treat analysis revealed that subjects receiving metadoxine ER showed statistically significant improvement in CAARS-INV total ADHD symptoms score (P = .02), higher rate of response (≥ 25% [P = .03] or ≥ 40% [P = .04] improvement) on the CAARS-INV total ADHD symptoms score, and improvement in TOVA score (P = .02) and AAQoL score (P = .01) compared with the placebo group. Improvements in ADHD symptoms (scored by CAARS-INV) were significantly different in subjects treated with metadoxine ER versus placebo as early as 2 weeks following treatment initiation. Metadoxine ER was generally well tolerated, with nausea (17% [10/58] vs 0% [0/59]), fatigue (31% [18/58] vs 27% [16/59]), and headaches (29% [17/58] vs 39% [23/59]) being the most frequently reported adverse effects for the metadoxine ER and placebo groups, respectively.

    CONCLUSIONS:

    Findings suggest that metadoxine ER is a well-tolerated and effective treatment for adults with ADHD.

    כות בים נוספים
    ראו פרסום

עוד פעילות על ידי Yaron

הצג Yaron את הפרופיל המלא

  • ראה את מי שאתה מכיר במשותף
  • הכירו
  • צור קשר Yaron ישירות
הצטרפו נוף הפרופיל המלא

פרופילים דומים אחרים

גלה פוסטים נוספים

אנשים אחרים ששמם Yaron Daniely

1 שם Yaron Daniely אחר נמצא על לינקדאין

הצג/י אנשים אחרים בשם Yaron Daniely

הוסף כישורים חדשים עם קורסים אלה

הצג את כל הקורסים